President, Chief Executive Officer and Director
Mark A. Goldsmith, M.D., Ph.D. has served as a member of our board of directors and as our President and Chief Executive Officer since November 2014. Since 2009, Dr. Goldsmith has served as a member of the board of directors of Constellation Pharmaceuticals, Inc., a biopharmaceutical company, where he also served as President and Chief Executive Officer from 2009 to 2012, as Chairman from 2012 to June 2016 and from March 2017 to present, and as Interim Executive Chairman from June 2016 to March 2017. Dr. Goldsmith was previously a Partner with Third Rock Ventures, a life sciences venture capital firm, from 2013 to 2015, and a Venture Partner with Third Rock from 2012 to 2013. Dr. Goldsmith served as President and Chief Executive Officer and as a member of the board of directors of Global Blood Therapeutics, a biopharmaceutical company, from 2012 to 2014. Dr. Goldsmith also served as President and Chief Executive Officer of Nurix, Inc., a drug discovery company, from 2012 to 2014. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies. Dr. Goldsmith received an A.B. from Princeton University in Biology and an M.D. and Ph.D. in Microbiology and Immunology from the School of Medicine of the University of California, San Francisco.
What is Mark A. Goldsmith's net worth?
The estimated net worth of Mark A. Goldsmith is at least $14.34 million as of December 16th, 2024. Dr. Goldsmith owns 325,056 shares of Revolution Medicines stock worth more than $14,341,471 as of January 5th. This net worth estimate does not reflect any other assets that Dr. Goldsmith may own. Additionally, Dr. Goldsmith receives a salary of $1,120,000.00 as Insider at Revolution Medicines. Learn More about Mark A. Goldsmith's net worth.
How old is Mark A. Goldsmith?
What is Mark A. Goldsmith's salary?
How do I contact Mark A. Goldsmith?
Has Mark A. Goldsmith been buying or selling shares of Revolution Medicines?
Mark A. Goldsmith has not been actively trading shares of Revolution Medicines in the last ninety days. Most recently, Mark A. Goldsmith sold 11,714 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a transaction totalling $531,815.60. Following the completion of the sale, the insider now directly owns 325,056 shares of the company's stock, valued at $14,757,542.40. Learn More on Mark A. Goldsmith's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 27 times. They sold a total of 238,507 shares worth more than $11,009,037.57. The most recent insider tranaction occured on December, 16th when COO Margaret A Horn sold 4,329 shares worth more than $196,536.60. Insiders at Revolution Medicines own 8.0% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 12/16/2024.
